Posology : מינונים

4.2.     Posology and method of administration

Posology
Hypertension

Adults

Initial dose
Do not start treatment with a new patient if it is not possible to reach a dose of 1 mg and 2 mg.


1
1 mg before bedtime is the starting dose for all patients and should not be exceeded.
Compliance with this initial dosage recommendation should be strictly observed to minimise potential for acute first-dose hypotensive episodes.

Subsequent doses
The single daily dosage may be increased by approximately doubling the dosage at weekly intervals to achieve the desired blood pressure response.

The usual maintenance dose is 2 mg to 10 mg once daily. Doses over 20 mg rarely improve efficacy and doses over 40 mg have not been studied.

If 1 or 2 mg dose is not optional, the physician should consider alternative therapies for these patients.


BPH
Adults

The dose of terazosin should be adjusted according to the patient’s response. The following is a guide to administration:

Initial dose
Do not start treatment with a new patient if it is not possible to reach a dose of 1 mg and 2 mg.
1 mg before bedtime is the starting dose for all patients and should not be exceeded. Strict compliance with this recommendation should be observed to minimise acute first-dose hypotensive episodes.

Subsequent dose
The dose may be increased by approximately doubling at weekly or bi-weekly intervals to achieve the desired reduction in symptoms. The maintenance dose is usually 5 to 10 mg once daily. Improvements in symptoms have been detected as early as two weeks after starting treatment with terazosin.

At present there are insufficient data to suggest additional symptomatic relief with doses above 10 mg once daily.

Transient side effects may occur at each titration step. If any side effects persist, consideration should be given to reducing the dose.

If administration is discontinued for more than several days, therapy should be re-instituted using the initial dose titration regimen. Do not start treatment after discontinuation if it is not possible to reach a dose of 1 mg and 2 mg.

If 1 or 2 mg dose is not optional, the physician should consider alternative therapies for these patients.

Elderly
Pharmacokinetic studies in the elderly indicate that no alteration in dosage recommendation is required.
Renal impairment

Pharmacokinetic studies indicate that patients with impaired renal function need no alteration in the recommended dosages.

Paediatric population

Safety and efficacy in children has not been established.
Method of administration
For oral use